- Report
- March 2023
- 254 Pages
Global
From €3059EUR$3,185USD£2,634GBP
€4370EUR$4,550USD£3,762GBP
- Report
- March 2024
- 150 Pages
From €4985EUR$5,190USD£4,292GBP
- Report
- October 2020
- 215 Pages
Global
From €3059EUR$3,185USD£2,634GBP
€4370EUR$4,550USD£3,762GBP
- Report
- June 2019
- 144 Pages
Global
From €3059EUR$3,185USD£2,634GBP
€4370EUR$4,550USD£3,762GBP
- Report
- April 2023
- 117 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- June 2020
- 112 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- July 2022
- 100 Pages
Global
From €2641EUR$2,750USD£2,274GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3122EUR$3,250USD£2,687GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2641EUR$2,750USD£2,274GBP
- Report
- November 2022
- 100 Pages
Global
From €2641EUR$2,750USD£2,274GBP
- Report
- October 2022
- 100 Pages
Global
From €2641EUR$2,750USD£2,274GBP
- Report
- October 2022
- 100 Pages
Global
From €2641EUR$2,750USD£2,274GBP
- Report
- July 2022
- 100 Pages
Global
From €2641EUR$2,750USD£2,274GBP
- Report
- July 2022
- 100 Pages
Global
From €2641EUR$2,750USD£2,274GBP
- Report
- July 2022
- 100 Pages
Global
From €2641EUR$2,750USD£2,274GBP
- Report
- August 2022
- 120 Pages
Global
From €4322EUR$4,500USD£3,721GBP
- Report
- January 2019
Global
From €4322EUR$4,500USD£3,721GBP
- Report
- August 2022
- 120 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- August 2021
- 120 Pages
Global
From €4274EUR$4,450USD£3,680GBP
- Report
- March 2019
- 108 Pages
Global
From €4130EUR$4,300USD£3,556GBP
The Dry Powder Inhaler (DPI) market is a segment of the respiratory drugs market. It is a device used to deliver medication to the lungs in the form of a dry powder. It is a convenient and efficient way to deliver medication to the lungs, as it does not require the use of a propellant gas. DPIs are used to treat a variety of respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They are also used to deliver vaccines and other medications.
DPIs are becoming increasingly popular due to their convenience and effectiveness. They are also cost-effective, as they require fewer components than other inhalers. Additionally, DPIs are easy to use and can be used by patients of all ages.
Several companies are involved in the DPI market, including GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. These companies are involved in the development, manufacture, and marketing of DPIs. Show Less Read more